Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Terminated 10Unknown 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Hepatocellular 6Leukemia, Myeloid, Acute 3Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Locally Advanced Thyroid Gland Carcinoma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1HCC 1Fibrolamellar hepatocellular carcinoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 48Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × Sorafenib × Clear all
NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Fudan University

Phase 2 Recruiting
620 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡